oxcarbazepine

(redirected from Oxtellar XR)
Also found in: Dictionary.
Related to Oxtellar XR: Trokendi XR

oxcarbazepine

 [oks″kahr-baz´ĕ-pēn]
an anticonvulsant used in the treatment of partial seizures, administered orally.

oxcarbazepine

Apo-Oxcarbazepine (CA), Trileptal

Pharmacologic class: Carboxamide derivative

Therapeutic class: Anticonvulsant

Pregnancy risk category C

Action

Blocks sodium channels in neural membranes, stabilizing hyperexcitable states and inhibiting neuronal firing and impulse transmission in brain

Availability

Oral suspension: 300 mg/5-ml bottle

Tablets: 150 mg, 300 mg, 600 mg

Indications and dosages

Adjunctive therapy for partial seizures

Adults: 300 mg P.O. b.i.d. May increase by up to 600 mg/day q week, to a maximum of 1,200 mg/day.

Children ages 2 to 16: Initially, 8 to 10 mg/kg/day P.O. to a maximum of 600 mg/day

Conversion to monotherapy for partial seizures

Adults: 300 mg P.O. b.i.d. May increase by 600 mg/day at weekly intervals over 2 to 4 weeks, to a maximum of 2,400 mg/day

Children ages 4 to 16: Initially, 8 to 10 mg/kg/day P.O. given in two divided doses, increased to a maximum of 10 mg/kg/day

Initiation of monotherapy

Adults: 300 mg P.O. b.i.d., increased by 300 mg/day P.O. q 3 days up to 1,200 mg/day

Children ages 4 to 16: Initially, 8 to 10 mg/kg/day P.O. given in two divided doses; increase by 5 mg/kg q 3 days to a maximum of 1,200 mg/day

Dosage adjustment

• Renal impairment
• Children ages 2 to younger than 4 weighing less than 20 kg (44 lb)

Contraindications

• Hypersensitivity to drug or its components

Precautions

Use cautiously in:
• renal impairment
• pregnant or breastfeeding patients
• children younger than age 2 (safety not established).

Administration

• Administer twice daily with or without food.
• Shake oral suspension well. If desired, mix in small glass of water.

Adverse reactions

CNS: dizziness, vertigo, drowsiness, fatigue, headache, ataxia, tremor, emotional lability

EENT: abnormal vision, diplopia, nystagmus, rhinitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia

Metabolic: hyponatremia

Skin: acne, rash

Other: thirst, allergic reactions, edema, lymphadenopathy

Interactions

Drug-drug.Carbamazepine, valproic acid, verapamil: decreased oxcarbazepine blood level

CNS depressants (including antidepressants, antihistamines, opioids, sedative-hypnotics): additive CNS depression

Felodipine, hormonal contraceptives: decreased blood levels of these drugs

Phenobarbital: decreased oxcarbazepine and increased phenobarbital blood levels

Phenytoin: increased phenytoin blood level

Drug-diagnostic tests.Sodium: decreased level

Drug-behaviors.Alcohol use: additive CNS depression

Patient monitoring

• Monitor neurologic status closely for changes in cognition, mood, wakefulness, balance, and gait.
• Check sodium level. Watch for signs and symptoms of hyponatremia.

Patient teaching

• Instruct patient to take at same time each day, with or without food.
• Tell patient to report vision changes and significant neurologic changes.
• Advise patient to have periodic eye exams.
• Tell female patient that drug makes hormonal contraceptives less effective.
• Inform patient that he may need frequent tests to check drug blood levels.
• Tell patient not to drink alcohol.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects him.
• As appropriate, review all significant adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

oxcarbazepine

/ox·car·baz·e·pine/ (oks″kahr-baz´ĕ-pēn) an anticonvulsant used in the treatment of partial seizures.

oxcarbazepine

[oks′kär-baz′ĕ-pēn]
an anticonvulsant used in the treatment of partial seizures. It is administered orally.
References in periodicals archive ?
Pharmaceutical company Supernus Pharmaceuticals (NasdaqGM:SUPN) reported on Wednesday that it has received a seventh patent from the US Patent and Trademark Office (USPTO) covering its novel once-daily extended-release oxcarbazepine product, Oxtellar XR.
Oxtellar XR is the first approved novel, oral once-daily extended release formulation of oxcarbazepine for the treatment of epilepsy.
Pharmaceutical company Supernus Pharmaceuticals (NasdaqGM:SUPN) reported on Thursday the receipt of a sixth patent from the US Patent and Trademark Office (USPTO) covering its novel once-daily extended-release oxcarbazepine product Oxtellar XR for the treatment of epilepsy.
Pharmaceutical company Supernus Pharmaceuticals (NasdaqGM:SUPN) on Wednesday reported the receipt of a patent from the US Patent and Trademark Office (USPTO) covering its novel once-daily extended-release oxcarbazepine product, Oxtellar XR.
Pharmaceutical company Supernus Pharmaceuticals (NasdaqGM:SUPN) reported on Thursday the receipt of the fourth patent covering its novel once-daily extended-release oxcarbazepine product, Oxtellar XR.
Specialist pharmaceutical company Supernus Pharmaceuticals Inc (NasdaqGM:SUPN) revealed on Tuesday the receipt of a third patent covering its novel once-daily extended-release oxcarbazepine product, Oxtellar XR.
On 19 October 2012, the company had received the FDA's approval for Oxtellar XR, a novel once-daily extended release antiepileptic drug indicated for adjunctive therapy in the treatment of partial seizures in adults and in children six to 17 years of age.
Each of our epilepsy products, Trokendi XR and Oxtellar XR, is now covered by two issued US patents.
The remainder will be used to fund the commercialisation of its approved and tentatively approved drugs, Oxtellar XR and Trokendi XR, to continue development of its pipeline products and for other general corporate purposes.
M2 PHARMA-October 23, 2012-Supernus Pharmaceuticals Inc wins FDA approval for Oxtellar XR in epilepsy following tentative approval of Trokendi XR(C)2012 M2 COMMUNICATIONS
M2 EQUITYBITES-February 4, 2013-Supernus Pharmaceuticals Inc unveils antiepileptic drug Oxtellar XR in the US market(C)2013 M2 COMMUNICATIONS http://www.
M2 EQUITYBITES-October 23, 2012-Supernus Pharmaceuticals Inc wins FDA approval for Oxtellar XR in epilepsy following tentative approval of Trokendi XR(C)2012 M2 COMMUNICATIONS http://www.